Objective Europe's consumers are increasingly requesting products that are organically and sustainably produced. At the same time, Europe has been lacking incentives to develop and bring to markets new marine products, without increasing pressure on natural resources.The innovation in question; a natural, sustainably produced medicine based on marine oils, addresses these challenges. It is based on the discovery that omega-3 oils have proven to have laxative effects. It offers parents and pediatricians a pain-free alternative to other pharmaceutical products, in a market where no new products have been introduced for decades. The innovation also paves the way for the full utilization of marine products, demonstrating that by-products can be of high value for other industries, including the pharmaceutical sector.The aim of the applicant is to develop this innovation all the way towards a market-ready, licensed pharmaceutical product. The pharmaceutical industry is one of the largest industries in the world in regards to revenues. Over 100 million people worldwide, suffer from constipation. The active ingredient of the innovation product would be a new and a unique addition to this growing market.The applicant seeks support to be able to obtain a solid analysis of the market potential for the innovation. If successfully brought to markets, it will reach the milestone of being the first non-generic, registered drug, tested in clinical trials in humans that was discovered, developed and produced in one of Europe's most peripheral corners, Iceland. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health scienceshealth sciencespublic healthepidemiologynatural sciencesbiological sciencesbiochemistrybiomoleculeslipids Programme(s) H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) BG-12-2014-1 - Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator LIPID PHARMACEUTICALS EHF Net EU contribution € 50 000,00 Address LAEKJARGOTU 12 101 REYKJAVIK Iceland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ísland Ísland Höfuðborgarsvæði Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
